Berkeley, MIT Clash Over Right to Profit From Gene-Editing Bonanza
There may be no clear winners once the dust settles on a patent interference case involving two marquee research universities and billions of dollars in licensing fees tied to a revolutionary gene-editing tool.
By Nate Robson|December 08, 2016
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
U.S. Patent & Trademark Office. (Photo: Diego M. Radzinschi/NLJ.)
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.